子宫内膜癌靶向药物治疗研究进展

Advances in targeted drug therapy for endometrial carcinoma

子宫内膜癌的化疗耐药性问题显著,迫切需要新的治疗方案。随着对肿瘤发病机制和信号传导通路的深入研究,以及表观遗传修饰作用机制的阐明,靶向药物研究为子宫内膜癌的治疗提供了新的方法和手段。本文综述了表皮生长因子受体拮抗剂、血管内皮生长因子抑制剂、PI3K/Akt/mTOR通路抑制剂、PD-1/PD-L1抑制剂和表观遗传修饰抑制剂等靶向药物在子宫内膜癌治疗领域的研究进展,为临床用药提供新思路。

The problem of chemoresistance of endometrial cancer is obvious, so new treatment is urgently needed. With the in-depth study of tumor pathogenesis and signal transduction pathway, as well as the explanation of epigenetic modification mechanism,targeted drug research provides new methods and means for the treatment of endometrial cancer. This article reviewed the research progress of epidermal growth factor receptor antagonists, vascular endothelial growth factor inhibitors, PI3K/Akt/mTOR pathway inhibitors, PD-1/PD-L1 inhibitors and epigenetic modification inhibitors in the field of endometrial cancer treatment, and provides new ideas for clinical medication.